Pure Global AI
NCT06383026Recruiting

Transgender and Gender-Diverse Breast Cancer Screening Pilot

Understanding Breast Cancer Risk and Screening in Transgender and Gender-Diverse Persons Through a Pilot Breast Cancer Screening Program
Medical College of WisconsinClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Breast Cancer
Drug/Device/Intervention
Breast Cancer Screening
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Medical College of Wisconsin
Location
Milwaukee, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 17, 2024
End date
Feb 01, 2028
Enrollment
130 participants
Primary outcome

Callback and Biopsy Rates after Breast Cancer Screening,Reflexive Thematic Analysis of the Physical, Cognitive, and Emotional Experience of Breast Cancer Screening in Transgender and Gender Diverse Persons,Reflexive Thematic Analysis on the Individual & System-Level Barriers to Breast Cancer Screening

Summary

This investigation is a prospective breast cancer screening study open to all transgender and
 gender-diverse persons (regardless of sex assigned at birth). Using a mixed methods approach,
 the study will 1) gather prospective quantitative breast imaging data in conjunction with
 gender-affirming therapy and family cancer history and 2) investigate TGD persons perceptions
 and experiences in the breast cancer screening program, and 3) identify individual and
 systems-level barriers to breast cancer screening.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedMalignant neoplasm: Breast, unspecifiedOther carcinoma in situ of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06383026
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06383026 through Pure Global AI's free database. This phase not specified trial is sponsored by Medical College of Wisconsin and is currently Recruiting. The study focuses on Breast Cancer. Target enrollment is 130 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.